WO2009095719A3 - Use of crac inhibitors and cysteinyl leukotriene inhibitors for treating allergy and asthma - Google Patents

Use of crac inhibitors and cysteinyl leukotriene inhibitors for treating allergy and asthma Download PDF

Info

Publication number
WO2009095719A3
WO2009095719A3 PCT/GB2009/050091 GB2009050091W WO2009095719A3 WO 2009095719 A3 WO2009095719 A3 WO 2009095719A3 GB 2009050091 W GB2009050091 W GB 2009050091W WO 2009095719 A3 WO2009095719 A3 WO 2009095719A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
crac
asthma
treating allergy
cysteinyl leukotriene
Prior art date
Application number
PCT/GB2009/050091
Other languages
French (fr)
Other versions
WO2009095719A2 (en
Inventor
Anant Parekh
Original Assignee
Isis Innovation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Limited filed Critical Isis Innovation Limited
Publication of WO2009095719A2 publication Critical patent/WO2009095719A2/en
Publication of WO2009095719A3 publication Critical patent/WO2009095719A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present disclosure provides methods, uses and products for use in treating disorders associated with mast cell activation. The present disclosure includes for example combinations of agents which inhibit Calcium Release Activated Calcium (CRAC) channels and agents which inhibit leukotriene activation of mast cells for use in treating disorders including allergic rhinitis and nasal polyposis.
PCT/GB2009/050091 2008-02-01 2009-01-30 Treatment of mast cell related disorders WO2009095719A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0801888.9A GB0801888D0 (en) 2008-02-01 2008-02-01 Treatment of mast cell related disorders
GB0801888.9 2008-02-01

Publications (2)

Publication Number Publication Date
WO2009095719A2 WO2009095719A2 (en) 2009-08-06
WO2009095719A3 true WO2009095719A3 (en) 2010-05-06

Family

ID=39204086

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/050091 WO2009095719A2 (en) 2008-02-01 2009-01-30 Treatment of mast cell related disorders

Country Status (2)

Country Link
GB (1) GB0801888D0 (en)
WO (1) WO2009095719A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795512A (en) * 2014-08-07 2017-05-31 第三共株式会社 Anti- Orai1 antibody

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2136820A4 (en) * 2007-03-05 2010-09-15 Univ Queensland A target for breast cancer therapy and/or diagnosis
TWI412369B (en) * 2010-06-07 2013-10-21 Univ Kaohsiung Medical Pharmaceutical composition for inhibiting cancer cell inflammation
WO2014153241A1 (en) 2013-03-14 2014-09-25 The Regents Of The University Of Michigan Treatment of staphylococcal disorders
EP2865758A1 (en) 2013-10-22 2015-04-29 Sylentis, S.A.U. siRNA and their use in methods and compositions for inhibiting the expression of the ORAI1 gene

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024138A1 (en) * 1997-10-13 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Pyrazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1024138A1 (en) * 1997-10-13 2000-08-02 Yamanouchi Pharmaceutical Co. Ltd. Pyrazole derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG W.C. ET AL.: "All-or-none activation of CRAC channels by agonist elicits graded responses in populations of mast cells.", J IMMUNOL, vol. 179, no. 8, 15 October 2007 (2007-10-15), pages 5255 - 5263, XP002558968 *
CHANG W.C. ET AL: "Close functional coupling between Ca2+ release-activated Ca2+ channels, arachidonic acid release, and leukotriene C4 secretion.", J BIOL CHEM, vol. 279, no. 29, 16 July 2004 (2004-07-16), pages 29994 - 29999, XP002558967 *
CHANG W.C.: "Local Ca2+ influx through Ca2+ release-activated Ca2+ (CRAC) channels stimulates production of an intracellular messenger and an intracellular proinflammatory signal.", J BIOL CHEM, vol. 283, no. 8, 21 December 2007 (2007-12-21), pages 4622 - 4631, XP002558966 *
GRAUL L ET AL: "Montelukast sodium, MK-476, MK-0476, L-706631, Singulair", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 22, no. 10, 1 January 1997 (1997-01-01), pages 1103, XP008082254, ISSN: 0377-8282 *
RAMIRES R. ET AL.: "Novel inhibitory effect on 5-lipoxygenase activity by the anti-asthma drug montelukast.", BIOCHEM BIOPHYS RES COMM, vol. 324, 2004, pages 815 - 821, XP002558969 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795512A (en) * 2014-08-07 2017-05-31 第三共株式会社 Anti- Orai1 antibody
CN106795512B (en) * 2014-08-07 2021-04-13 第一三共株式会社 anti-Orai 1 antibodies

Also Published As

Publication number Publication date
WO2009095719A2 (en) 2009-08-06
GB0801888D0 (en) 2008-03-12

Similar Documents

Publication Publication Date Title
PH12017500930A1 (en) Hsp90 inhibitor combinations
WO2010065435A3 (en) System and method for mechanical closure of wounds
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
GB0821929D0 (en) Percutaneous devices for separating tissue, kits and methods of using the same
EP2318088A4 (en) Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation
WO2011057282A3 (en) Tissue closure devices, device and systems for delivery, kits and methods therefor
IL209985A0 (en) Systems, apparatuses, and methods for providing non-transcranial electrotherapy
WO2010118312A3 (en) Tissue closure devices, device and systems for delivery, kits and methods therefor
WO2009109532A9 (en) Use of defensins against tuberculosis
WO2009115572A3 (en) Novel heterocyclic compounds and uses therof
BRPI0920586A2 (en) separation device for use in the separation, characterization and / or identification of microorganisms.
IL200632A0 (en) First aid system, procedure for its operation, and protable first-aid device for use especially in the system
WO2007126824A3 (en) Methods and systems for sterilization
WO2012080833A3 (en) Controlled release dosage forms
EG26112A (en) Sprinkler with an integrated valve, and fire-extinguishing system using same
WO2008030427A3 (en) Passive in vivo substance spectroscopy
EP2136814A4 (en) Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
HK1158053A1 (en) Apparatus for mobilization of the body, and use of such an apparatus
EP2030615A3 (en) Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
WO2009095719A3 (en) Use of crac inhibitors and cysteinyl leukotriene inhibitors for treating allergy and asthma
EP2306889A4 (en) Ophthalmic apparatuses, systems and methods
WO2008086505A3 (en) Methods of using il-31 to treat airway hyper-responsiveness and asthma
IL211642A0 (en) Method for the treatment of substrates, substrate and treatment device for carrying out said method
WO2010033392A3 (en) Methods and kits for treating cluster headache disorders
GB2465814B (en) Method,composition and device for the treatment of enzymes and saccharides disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09705359

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09705359

Country of ref document: EP

Kind code of ref document: A2